Last updated: February 20, 2026
What is the Drug Identified by NDC 00093-0787?
NDC 00093-0787 corresponds to Galantamine Hydrobromide, marketed under the brand name Reminyl, used primarily for the treatment of mild to moderate Alzheimer’s disease. It is an acetylcholinesterase inhibitor that enhances cholinergic function in the brain.
Market Landscape
Current Market Size
The global Alzheimer's therapeutics market was valued at approximately USD 8 billion in 2022. Galantamine's contribution is estimated at USD 250-300 million, representing roughly 3-4% of the overall market.
Key Competitors
- Donepezil (Aricept)
- Rivastigmine (Exelon)
- Memantine (Namenda)
Galantamine competes predominantly with Donepezil, which holds the largest market share, followed by Rivastigmine.
Patent Status
The original patent for Galantamine expired in 2012, leading to the entry of generic formulations. Brand-name drugs discontinued or phased out in many regions, pushing the market toward generics.
Launch and Approvals
- FDA approval was granted in 2001.
- Several generic manufacturers entered the US market post-2012.
- Market expansion in emerging economies is ongoing, with favor from regulatory agencies.
Pricing Trends and Projections
Historical Pricing
| Year |
Brand Name (Reminyl) |
Average Wholesale Price (USD) per 30-day supply |
Generic (per 30-day supply) |
| 2010 |
Reminyl |
350 |
250 |
| 2015 |
Reminyl discontinued |
N/A |
70 |
| 2018 |
Generic versions |
60-80 |
60 |
| 2022 |
Generic versions |
55-75 |
55-70 |
Current Price Range
- Brand-name Reminyl: No longer available; historical prices ranged USD 350/month.
- Generics: USD 55-70/month (dependent on region and distributor).
Factors Driving Price Changes
- Generic Competition: Post-2012, multiple generics reduced prices sharply.
- Manufacturing Costs: Remain stable; patents expired, leading to lower R&D costs for generics.
- Regulatory Environment: Variations in approval processes affect market entry and pricing.
- Market Penetration in Emerging Economies: Facilitates price reduction due to increased supply.
Price Projection (2023-2028)
| Year |
Expected Average Wholesale Price (USD) per 30-day supply |
| 2023 |
50-70 |
| 2024 |
50-70 |
| 2025 |
50-65 |
| 2026 |
45-60 |
| 2027 |
45-60 |
| 2028 |
40-55 |
Declining trend due to increased generic competition and market saturation.
Market Opportunities and Challenges
Opportunities
- Expansion into emerging markets due to lower prices.
- Potential label extensions for other neurodegenerative diseases.
- Development of combination therapies with existing Alzheimer’s treatments.
Challenges
- Competition from newer therapeutics with different mechanisms (e.g., Aducanumab).
- Limited efficacy data for long-term benefits.
- Regulatory barriers in different regions.
Regulatory and Patent Perspectives
- Recent regulatory scrutiny focusing on clinical efficacy claims.
- Patent expirations drive price declines but also open the market for generics.
- Ongoing clinical trials evaluating efficacy in combination therapy or novel indications may influence future prices and market share.
Key Takeaways
- The market for Galantamine (NDC 00093-0787) is mature, with fixed or declining prices due to patent expirations.
- Generics dominate the market, pushing prices toward USD 40-70/month in the next 5 years.
- Market growth is driven mainly by emerging economies and potential off-label uses, though competition from newer drugs remains a concern.
- Significant opportunities exist in combination therapy and new indications; challenges include efficacy perceptions and competing drugs.
FAQs
Q1: What factors most influence the price of Galantamine?
Patent status, generic competition, manufacturing costs, and regional regulatory policies.
Q2: How does the market share of Galantamine compare with other Alzheimer’s drugs?
Galantamine has a smaller market share relative to Donepezil, which dominates due to longer presence and deeper clinician familiarity.
Q3: Are there upcoming patent protections or exclusivities?
No; patent protection expired in 2012, with generics available globally.
Q4: What are the primary markets for Galantamine?
Developed countries like the US and Europe, with increasing use in China, India, and Brazil.
Q5: How might future clinical data influence the market?
Positive evidence of efficacy in new indications or combination therapies could lead to revenue increases; negative data could further diminish its market relevance.
References
[1] Grand View Research. (2022). Alzheimer's Therapeutics Market Size, Share & Trends Analysis Report.
[2] U.S. Food and Drug Administration. (2022). Drugs@FDA Database.
[3] IQVIA. (2022). National Prescription Audit.
[4] Statista. (2023). Alzheimer’s Disease Treatment Market Revenue Forecast.
